COMPASS Pathways to Launch Phase II Trial of COMP360 Psilocybin Therapy for Post-Traumatic Stress Disorder

COMPASS Pathways, Inc. announced it will be conducting a Phase II clinical trial to assess the safety and tolerability of COMP360 psilocybin therapy in post-traumatic stress disorder.